Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 13/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 13/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 12/20 | 1.00 |
| ▸ | HSD11B1 | P28845 | 18/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL590208 | 1.00 | CYP2C9 (1.00) | CYP2C9CYP2C19CYP3A4HSD11B1 | |
| SCHEMBL117926 | 0.90 | HSD11B1 (0.92) | CYP2C9CYP2C19CYP3A4HSD11B1 | |
| SCHEMBL116854 | 0.90 | HSD11B1 (1.00) | CYP2C9CYP2C19CYP3A4HSD11B1 | |
| SCHEMBL117927 | 0.90 | HSD11B1 (0.92) | CYP2C9CYP2C19CYP3A4HSD11B1 | |
| SCHEMBL116853 | 0.90 | HSD11B1 (1.00) | CYP2C9CYP2C19CYP3A4HSD11B1 | |
| SCHEMBL118399 | 0.89 | HSD11B1 (1.00) | CYP2C9CYP2C19CYP3A4HSD11B1 | |
| SCHEMBL118398 | 0.89 | HSD11B1 (1.00) | CYP2C9CYP2C19CYP3A4HSD11B1 | |
| SCHEMBL118211 | 0.88 | HSD11B1 (0.86) | CYP2C9CYP2C19CYP3A4HSD11B1 | |
| SCHEMBL589114 | 0.88 | HSD11B1 (1.00) | CYP2C9CYP2C19CYP3A4HSD11B1 | |
| SCHEMBL118212 | 0.88 | HSD11B1 (0.86) | CYP2C9CYP2C19CYP3A4HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2687525-B1 | CYCLIC INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INT (DE) | 2015-09-23 | — | — | EP | disclosed |
| EP-2324017-B1 | INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INT (DE) | 2014-12-31 | — | — | EP | disclosed |
| US-8846668-B2 | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2183228-B1 | CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-8754076-B2 | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 | Vitae Pharmaceuticals, Inc./Boehringer-Ingelheim (DE) | 2014-06-17 | — | — | US | disclosed |
| US-8680093-B2 | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8673899-B2 | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673899-B2 | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| EP-2687525-A1 | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 | Boehringer Ingelheim International GmbH (DE) | 2014-01-22 | — | — | EP | disclosed |
| US-8629138-B2 | — | — | 2014-01-14 | — | — | US | disclosed |
| US-20110021512-A1 | Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. | 2011-01-27 | — | — | US | disclosed |
| US-20110015157-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals ,Inc. | 2011-01-20 | — | — | US | disclosed |
| US-20110009402-A1 | Cyclic Inhibitors of 11Beta-Hydroxysteroid Dehydrogenase 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2011-01-13 | — | — | US | disclosed |
| US-20100331320-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20100331320-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20100256363-A1 | SYNTHESIS OF INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| EP-2183228-A1 | CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2010010150-A1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009134400-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009017664-A1 | CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021512-A1 | Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD11B2, HSD3B1 | CYP2C9 435/4885CYP2C19 462/4885CYP3A4 603/4885 |
| US-20110009402-A1 | Cyclic Inhibitors of 11Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD11B2, HSD3B1 | CYP2C9 315/4885CYP2C19 248/4885CYP3A4 514/4885 |
| US-20100331320-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | CYP2C9 307/4885CYP2C19 246/4885CYP3A4 500/4885 |
| US-20100256363-A1 | SYNTHESIS OF INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD11B2, HSD17B1 | CYP2C9 721/4885CYP2C19 307/4885CYP3A4 526/4885 |
| US-20110015157-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | CYP2C9 230/4885CYP2C19 175/4885CYP3A4 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.